Deutsche Bank AG Buys New Position in Disc Medicine, Inc. $IRON

Deutsche Bank AG acquired a new position in Disc Medicine, Inc. (NASDAQ:IRON) in the 2nd quarter, Holdings Channel reports. The firm acquired 30,643 shares of the company’s stock, valued at approximately $2,241,000.

Other hedge funds and other institutional investors also recently modified their holdings of the company. RA Capital Management L.P. lifted its holdings in Disc Medicine by 25.3% in the fourth quarter. RA Capital Management L.P. now owns 1,976,132 shares of the company’s stock worth $156,925,000 after buying an additional 399,026 shares during the period. Vanguard Group Inc. boosted its position in shares of Disc Medicine by 22.1% during the fourth quarter. Vanguard Group Inc. now owns 1,767,680 shares of the company’s stock valued at $140,371,000 after purchasing an additional 319,621 shares in the last quarter. Price T Rowe Associates Inc. MD boosted its position in shares of Disc Medicine by 28.0% during the fourth quarter. Price T Rowe Associates Inc. MD now owns 1,698,005 shares of the company’s stock valued at $134,839,000 after purchasing an additional 371,576 shares in the last quarter. JPMorgan Chase & Co. grew its stake in Disc Medicine by 110.0% in the fourth quarter. JPMorgan Chase & Co. now owns 1,581,127 shares of the company’s stock worth $125,557,000 after purchasing an additional 828,248 shares during the period. Finally, Wellington Management Group LLP grew its stake in Disc Medicine by 7.7% in the fourth quarter. Wellington Management Group LLP now owns 1,518,274 shares of the company’s stock worth $120,566,000 after purchasing an additional 108,197 shares during the period. Hedge funds and other institutional investors own 83.70% of the company’s stock.

Analysts Set New Price Targets

IRON has been the topic of a number of research reports. Wall Street Zen upgraded shares of Disc Medicine from a “sell” rating to a “hold” rating in a report on Saturday, August 1st. HC Wainwright increased their price target on shares of Disc Medicine from $118.00 to $120.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Weiss Ratings reissued a “sell (d-)” rating on shares of Disc Medicine in a research report on Friday, July 17th. Morgan Stanley reissued an “overweight” rating and set a $90.00 price objective on shares of Disc Medicine in a research note on Monday, August 17th. Finally, Wedbush restated an “outperform” rating and issued a $88.00 price objective on shares of Disc Medicine in a report on Wednesday, June 10th. Ten research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the company’s stock. Based on data from MarketBeat, Disc Medicine presently has an average rating of “Moderate Buy” and a consensus target price of $106.50.

Insiders Place Their Bets

In other Disc Medicine news, insider Rahul Khara sold 5,000 shares of Disc Medicine stock in a transaction on Thursday, August 6th. The stock was sold at an average price of $80.00, for a total value of $400,000.00. Following the completion of the sale, the insider owned 52,324 shares of the company’s stock, valued at approximately $4,185,920. This trade represents a 8.72% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through this link. Also, COO Jonathan Yen-Wen Yu sold 8,796 shares of the company’s stock in a transaction on Tuesday, August 25th. The shares were sold at an average price of $83.12, for a total value of $731,123.52. Following the transaction, the chief operating officer directly owned 54,324 shares in the company, valued at approximately $4,515,410.88. The trade was a 13.94% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. In the last quarter, insiders sold 153,612 shares of company stock valued at $11,431,811. Corporate insiders own 3.76% of the company’s stock.

Disc Medicine Stock Down 0.1%

NASDAQ:IRON opened at $82.55 on Friday. The company has a debt-to-equity ratio of 0.09, a quick ratio of 24.14 and a current ratio of 24.14. The firm has a market cap of $316.58 million, a P/E ratio of -12.55 and a beta of 1.00. Disc Medicine, Inc. has a fifty-two week low of $40.00 and a fifty-two week high of $99.50. The firm has a 50-day simple moving average of $76.79 and a two-hundred day simple moving average of $69.97.

Disc Medicine (NASDAQ:IRON) last posted its quarterly earnings results on Thursday, July 30th. The company reported ($1.54) EPS for the quarter, beating analysts’ consensus estimates of ($1.71) by $0.17. Analysts predict that Disc Medicine, Inc. will post -6.61 earnings per share for the current fiscal year.

Disc Medicine Company Profile

Disc Medicine, Inc (NASDAQ: IRON) is a clinical-stage biotechnology company focused on discovering and developing precision medicines that restore normal cellular function in severe genetic and acquired diseases. The company employs a chemistry-driven approach to identify small molecules that selectively modulate RNA-binding proteins or splicing regulatory pathways. By leveraging proprietary screening and medicinal chemistry platforms, Disc Medicine aims to address diseases with high unmet medical needs and limited treatment options.

The company’s pipeline is anchored by lead programs targeting neuromuscular and hematological disorders.